Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Triomaxx is a neurotropic fixed-dose combination therapy containing high doses of vitamins B1 (thiamine), B6 (pyridoxine), and B12 (cyanocobalamin), typically formulated with lidocaine hydrochloride to facilitate painless intramuscular administration. It is primarily indicated for the treatment of inflammatory and degenerative diseases of the nerves and locomotor system, including various forms of neuralgia, neuritis, and polyneuropathy (such as diabetic and alcoholic types). Thiamine acts as a cofactor in carbohydrate metabolism and energy supply to nerve cells; pyridoxine is essential for the synthesis of neurotransmitters like GABA, dopamine, and serotonin; and cyanocobalamin is critical for myelin sheath formation and DNA synthesis. The combination is designed to support nerve regeneration, improve metabolic function in nervous tissue, and provide analgesic effects. It is distributed by Max Pharma in Central Asian markets, including Uzbekistan and Tajikistan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Triomaxx.